MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
4523.T stock logo

4523.T

Eisai Co., Ltd.

$4688
1
 (0.02%)
[ms_data_label text=’Delayed data’]
Exchange:  JPX
Market Cap:  1.323T
Shares Outstanding:  286.616M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – Specialty & Generic
   
CEO:  Haruo Naito
Full Time Employees:  11067
Address: 
4-6-10, Koishikawa
Tokyo
112-8088
JP
Website:  https://www.eisai.co.jp
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer’s disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202220232024
Revenue744,402,000741,751,000789,400,000
Gross Profit543,475,000563,774,000597,233,000
EBITDA79,201,00086,150,000103,727,000
Operating Income39,220,00046,752,00049,240,000
Net Income55,432,00042,407,00046,433,000

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202220232024
Total Assets1,263,350,0001,393,799,0001,386,547,000
Total Liabilities440,779,000494,825,000520,577,000
Total Stockholders Equity799,959,000875,614,000841,417,000
Total Debt170,918,000206,746,000231,175,000
Cash and Cash Equivalents267,350,000304,678,000265,561,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202220232024
Operating Cash Flow-1,772,00055,993,00030,117,000
Capital Expenditure-22,576,000-14,321,000-11,933,000
Free Cash Flow-24,348,00041,672,00018,184,000
Net Income55,432,00042,407,00046,433,000
Net Change in Cash-42,283,00037,328,000-39,117,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)973,359,533.573Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,056,683,950.842Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)1,018,419,088Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)122,115,583.298Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)132,569,284.595Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)127,768,657.607Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)98,761,236.047Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)109,906,813.794Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)104,788,457.253Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)455,501,053.399Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)494,494,209.094Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)476,587,480.150Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)369.580Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)387.630Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)348.320Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)2Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
1.71
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
32.27
?Enterprise Value
 (TTM)
: 
1.291T  ?EV/FCF
 (TTM)
: 
17.7
?Dividend Yield
 (TTM)
: 
0.03  ?Payout Ratio
 (TTM)
: 
1.06
?ROE
 (TTM)
: 
0.05  ?ROIC
 (TTM)
: 
0.03
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.26
?P/B
 (TTM)
: 
1.55  ?Current Ratio
 (TTM)
: 
2.17

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
4,327.44Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate T Intrinsic Value

Common questions about 4523.T valuation

Is Eisai Co., Ltd. (4523.T) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Eisai Co., Ltd. (4523.T) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is 4523.T a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 4523.T trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is 4523.T’s P/E ratio?

You can see 4523.T’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for 4523.T?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is 4523.T a good long-term investment?

Whether 4523.T fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

4523.T

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

0.02
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low: 3659   Year High: 5349
Price Avg 50: 4925.42   Price Avg 200: 4696.48
Volume: 875000   Average Volume: 1.304M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read